GSK enters agreement to acquire 35Pharma Inc.
Includes HS235, a potentially best-in-class activin signaling inhibitor in clinical development for treatment of cardiopulmonary diseasesWeiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)
Quelle: EN, GlaxoSmithKline